BTIG Research started coverage on shares of Immunocore (NASDAQ:IMCR – Get Rating) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $85.00 target price on the stock.
Separately, HC Wainwright reaffirmed a buy rating and set a $80.00 target price on shares of Immunocore in a research note on Tuesday, July 5th.
Immunocore Trading Up 8.7 %
NASDAQ:IMCR opened at $54.40 on Tuesday. The firm has a 50 day moving average of $38.95 and a 200 day moving average of $31.82. The stock has a market capitalization of $2.39 billion, a price-to-earnings ratio of -14.78 and a beta of 0.09. Immunocore has a 52 week low of $18.43 and a 52 week high of $54.94. The company has a quick ratio of 4.57, a current ratio of 4.58 and a debt-to-equity ratio of 0.39.
Institutional Trading of Immunocore
Institutional investors and hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. acquired a new position in shares of Immunocore during the 4th quarter worth $34,000. Royal Bank of Canada purchased a new position in Immunocore in the 1st quarter valued at about $79,000. Bank of America Corp DE lifted its holdings in Immunocore by 92.0% in the 1st quarter. Bank of America Corp DE now owns 6,832 shares of the company’s stock valued at $204,000 after purchasing an additional 3,274 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Immunocore in the 1st quarter valued at about $218,000. Finally, Dalton Investments LLC purchased a new position in shares of Immunocore during the 2nd quarter worth about $373,000. Hedge funds and other institutional investors own 51.16% of the company’s stock.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.
- Get a free copy of the StockNews.com research report on Immunocore (IMCR)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.